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Abstract This was a double-blind clinical trial designed 
to assess the efﬁcacy and safety of the cinnarizine (CIN) in 
patients with migraine who were refractory to propranolol 
and tricyclic antidepressants in comparison with sodium 
valproate (SV) to investigate whether CIN could be at least 
as effective as SV. A total of 125 patients were treated in a 
treatment period of 12 weeks. All patients had at least one 
intake of trial medication and 2-week post baseline efﬁcacy 
observation which all were included in the ITT analysis. Of 
the 125 subjects treated, 46 discontinued prematurely: 25 
from the CIN and 21 from the SV group. The main reasons 
for premature discontinuation were: lost to follow up (25/ 
46, 63.2%), insufﬁcient response (16/46, 20%), and adverse 
events (5/46, 12.8%). No statistically signiﬁcant inter­
group differences in the number of discontinuation was 
observed (p [ 0.05). In both groups, number of attacks, 
intensity, and duration of attacks signiﬁcantly decreased 
(p \ 0.05). No statistically signiﬁcant inter-group differ­
ences were observed regarding the mean number of attacks, 
duration, and intensity of migraine attacks for any of the 
time intervals analysed, except for the mean reduction of 
third and fourth visits intensity from baseline which were 
signiﬁcantly different in two groups (p \ 0.05), with the 
CIN group showing more reduction. Analysis of the 
number of responders showed that in the CIN group 61.2% 
subjects were responders, and 63.8% in the SV group. No 
statistically signiﬁcant differences between the treatment 
groups were found for any of the secondary parameters. 
Overall 26 subjects reported one or more adverse events 
during the study period: 13 subjects in each group. Five 
subjects discontinued prematurely due to adverse events; 
two in the CIN group with signiﬁcant weight gain, and 3 in 
the SV group with signiﬁcant weight gain and severe tre­
mor. These results suggest that CIN is an effective and safe 
prophylactic agent even in severe migraine headache. 
Keywords Migraine prophylaxis · Cinnarizine · 
Sodium valproate 
Introduction 
Migraine is one of the most common headache conditions 
known to mankind, with prevalence of 17% for women, 
6% for men, and 4% for children [1], and often associated 
with signiﬁcant disability and impaired quality of life, 
adversely affecting daily activity and work related pro­
ductivity for many persons [2]. Prophylactic treatment for 
migraine is used in cases where frequency and severity of 
attacks warrant such an intervention. The most frequently 
used drugs for migraine prevention are b-blockers, calcium 
channel blockers, serotonin antagonists, monoamine oxi­
dase inhibitors, and anticonvulsant agents [3–6]. 
Cinnarizine (CIN) is an L-type calcium channel blocker, 
which inhibits contractions of vascular smooth muscle cells 
[7], directly inhibits vestibular hair cells stimulation [8], 
and has antihistaminic actions [9]; all these mechanisms 
can potentially contribute to its preventive effects on 
migraine. 
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In 1993, 1999 and more recently in 2001, The Italian 
Guidelines for the treatment of headache included the CIN 
among the drugs with the higher levels of recommendation 
(ﬁrst choice drug in 1993 and 1999, group II level of rec­
ommendation in 2001, comparable for instance to 
metoprolole) [10, 11]. Interestingly, the CIN is not men­
tioned in the guidelines produced by other scientiﬁc 
societies [11–14] and apart from few ‘‘local’’ reports [15– 
19] no study has systematically evaluated this drug in 
migraine prophylaxis. 
Rossi et al. [17] ﬁrst showed the effectiveness and tol­
erability of CIN in migraine prophylaxis after the 
publication of international headache society (IHS) diag­
nostic criteria and guidelines for clinical trials [20, 21]. 
Amelin et al. [19] reported a great reduction in migraine 
attacks frequency when studying vertigolitic effect of CIN 
in a group of migraneurs. In a recently published open-
label trial, we showed signiﬁcant improvement in migraine 
headache frequency, duration, and intensity of headache 
[18]. 
Several anticonvulsants have also been investigated in 
the treatment of migraine, which sodium valproate (SV) 
has been shown to be more effective than others [22]. In 
clinical trials, about 30–50% of patients taking SV have 
achieved a 50% reduction in headache frequency [23–25]. 
No studies are available comparing CIN with SV for 
prevention of migraine headache. 
The aim of this trial was to demonstrate the efﬁcacy and 
safety of the CIN in patients with migraine who were 
refractory to propranolol and tricyclic antidepressants, in 
comparison with SV to investigate whether CIN could be at 
least as effective as SV. 
Subjects and methods 
Overall trial design and plan 
We used a comparative trial characterized by a run-in 
phase followed by a double-blind period during which the 
subjects received either CIN or SV. We did not use any 
placebo because the subjects have had intractable migraine 
and it was immoral to use no drug during 12 weeks. The 
trial was approved by the ethics committee of Tehran 
University of Medical Sciences, and all patients were 
informed consent about the aim of the study and gave 
informed consent prior to entering the study. 
The trial started with a no medication run-in phase of 
4 weeks, in which, the patients were allowed to use anal­
gesic drugs to treat acute migraine attacks. This phase was 
included in the study to familiarize patients with trial pro­
cedure, establish a subject’s competence to correctly ﬁll in 
the diary, and having a baseline data. At the end of this 
screening phase, subjects were randomized to CIN 75 mg or 
SV 600 mg, and the 12 week double-blind treatment phase 
was started, during which visits were scheduled at 2, 4, 8, 
and 12 weeks. A total of 125 patients were expected to be 
needed to prove that CIN was at least as effective as SV. 
Inclusion criteria was as follows:
 
Male or female. Age 16–60 years;
 
Having experienced 3–10 migraine attacks every month
 
for the preceding 2 months;
 
Migraine present for at least 1 year;
 




Onset of migraine before the age of 50 years.
 
Exclusion criteria were: 












Serious disease (diabetes, serious hepatic, renal, cardio­
vascular or malignant illness); Pregnancy, lactating or
 
child-bearing potential without adequate contraception.
 
Known hypersensivity to CIN or SV.
 
Treatment 
After run-in phase one group of subjects received CIN 
tablets and another group received SV tablets three times 
daily for 12 weeks. Both drugs were white and round, but 
not exactly similar. All tablets were put in the same drug 
packages. Random allocation of patients to study groups 
were provided by balanced block randomization using 
block of six, in that both patient and physician were not 
aware of the treatment type that the patient received. At the 
start of the trial (visit 0), a complete medical history and 
speciﬁc migraine history was recorded and a general 
physical and neurological examination, blood counts and 
liver function tests were performed. The subjects were 
given a dairy in which all migraine attacks, duration of 
attacks (hours), intensity of attacks (assessed by a 10-score 
Visual Analog Scale (VAS) with 0 indicating no pain and 
10 indicating the worst pain imaginable), number of days 
without migraine, and time between two consecutive 
attacks had to be recorded. From visit 1 (start of double-
blind period) through visit 5 (end of week 12), the subject’s 
dairy was checked and collected. Laboratory test included 
blood count and liver function tests also performed at the 
end of the trial. Refractory headache was classiﬁed in those 
who had been refractory to all previous forms of therapy 
including b-blocker and anti depressants. 
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The main end points were the mean attack frequency per 
4 weeks in the entire double-blind period and the number 
of responders. The percentage of responders deﬁned as 
subjects for whom the attack frequency decreased by 
C50% compared to run-in per visits in the double-blind 
period. Mean duration of migraine attacks, mean intensity 
of the attacks, mean number of days without migraine, and 
mean time between two consecutive attacks were second 
parameters. 
The factors considered to have a possible prognostic 
value for therapeutic responsiveness to each drug were type 
of migraine (with or without urea), sex, age, family history 
(maternal or paternal), frequency, duration, and intensity of 
migraine attacks, age of migraine onset, duration of 
migraine history, presence of concomitant symptoms 
(nausea vomiting, photophobia and phonophobia), and 
resistance to prophylactic treatment. 
From visit 1 on, the subjects was asked whether he/she 
had experienced any adverse events. Special attention was 
paid to the occurrence of sedation, weight gain and extra 
pyramidal symptoms. 
Statistics 
All randomized subjects with at least one intake of the trial 
medication and one post baseline efﬁcacy observation 
period of at least 2 weeks were deﬁned as intention-to-treat 
populations. If a 50% decrease in migraine frequency is 
considered to be a clinically response on the basis of pre-
vious estimates of SD of 2.50, and accounting for pairwise 
comparisons, subjects per group were expected to be nee-
ded to prove that CIN was as effective as SV at the 5%­
level, with a power of 80%. Statistical analysis was based 
on an intention-to-treat principle. 
Baseline between-group comparability with respect to 
demographic variables and efﬁcacy parameters were 
assessed. Descriptive statistics for each treatment sepa­
rately and for the total population were provided. The 
Student’s t test for independent samples and analysis of 
variance with repeated measures over time was applied to 
investigate treatment comparability with respect to con-
tinues variables. Paired-Student’s t test was performed to 
study the comparability between basal and post-treatment 
periods. Results are expressed as mean and p \ 0.05 was 
considered statistically signiﬁcant. The analysis were done 
on a personal computer using SPSS for windows, and 
conﬁdence interval analysis software. 
Results 
The trial was run from May 2002 to April 2004. In total 
125 subjects were recruited in the study and all were 
randomized; 67 were assigned to CIN 75 mg and 58 to SV 
800 mg. All patients had at least one intake of trial medi­
cation and 2-week post baseline efﬁcacy observation which 
all were included in the ITT analysis. 
Of the 125 subjects treated, 46 discontinued prema­
turely: 25 from the CIN and 21 from the SV group. The 
main reasons for premature discontinuation were: lost of 
follow up (25/46, 63.2%), insufﬁcient response (16/46, 
20%), and adverse events (5/46, 12.8%). No statistically 
signiﬁcant inter group differences in the number of dis-
continuation was observed (p [ 0.05). 
The demographic data of the 125 subjects randomized 
and treated was shown in Table 1. Over all 80.8% of the 
subjects were female, and the median ages in the two 
groups was 34 years with minima and maxima ranging 
from 13 to 60 years. Demographic data were not signiﬁ­
cantly different between the two groups. 
Table 2 summarized the efﬁcacy parameters in the ITT 
population per visits during the double-blind period in two 
treatment groups. Analysis of the number of responders 
showed that in the CIN group 41 (61.2%) subjects were 
Table 1 Characteristics of patients by treatment group at baseline 
Baseline characteristics Cinnarizine 
(n = 67) 
Sodium valproate 
(n = 58) 
Sex (male/female) 11/56 13/45 
Mean age (years) 34.5 (13–60) 33.6 (16–55) 
Mean age of migraine onset 25.5 (9–45) 22.5 (10–40) 
(years) 
Family history (positive) 41 (61.2%) 35 (60.3%) 
Mean attack frequency (n) 7.4 (3–10) 6.9 (3–10) 
Mean duration of attack (h) 14.6 (4–24) 14.3 (4–24) 
Mean intensity of the attack 8.4 (4–10) 8.1 (4–10) 
(VAS) 
Mean number of days without 
attacks (h) 
22.6 (20–27) 23.1 (20–27) 
Mean time between two 
consecutive attacks (h) 
4.6 (3–10) 5.1 (3–10) 
Concomitant symptoms 
Nausea 59 (88.1%) 51 (87.9%) 
Vomiting 28 (41.8%) 25 (43.1%) 
Photophobia 41 (61.2%) 40 (69.0%) 
Phonophobia 54 (80.6%) 42 (72.4%) 
Response to propranolol 
Without response 10 (14.9%) 7 (12.1%) 
Weak 34 (50.7%) 30 (51.7%) 
Partially response 23 (34.3%) 21 (36.2%) 
Response to TCA 
Without response 8 (11.9%) 9 (15.5%) 
Weak 36 (53.7%) 29 (50.0%) 
Partially response 23 (34.3%) 20 (34.5%) 
VAS visual analogue scale 
123
 
80 J Headache Pain (2008) 9:77–82 
Table 2 Comparison of efﬁcacy parameters in the intention-to treat (ITT) population after therapy and the differences with baseline 
Efﬁcacy parameters After therapy Intergroup differences (CI 95%) 
Cinnarizine Sodium valproate 
n = 67 n = 58 
Mean attack frequency (n), mean ± SD 3.12 ± 1.70 3.00 ± 1.61 0.12 (-0.62, 0.87)* 
Percentage of respondersa (%) 41 (61.2%) 37 (63.8%) – 
Mean duration of the attack (h), mean ± SD 10.01 ± 7.10 8.97 ± 7.06 1.03 (-2.16,4.23)* 
Mean intensity of the attack (VAS), mean ± SD 5.03 ± 1.74 5.36 ± 2.03 -0.32 (-1.18,0.53)* 
Mean number of days without attacks (days), mean ± SD 26.86 ± 1.84 26.90 ± 1.80 -0.39 (-0.086,0.78)* 
Mean time between two consecutive attacks (h), mean ± SD 12.26 ± 6.31 12.06 ± 6.33 0.19 (-2.66,3.05)* 
VAS visual analogue scale 
*No signiﬁcant differences. p [ 0.05 
a Responders: decreased in attack frequency with at least 50% as compared to run-in 
responders, and 37 (63.8%) in the VS group. Statistical 
testing showed that CIN treatment was at least as effective 
as SV with respect to frequency of migraine attacks 
decreased, and the percentage of the responders. 
Fig. 1 summarize the mean number of attacks at the 
baseline, per visits during the double-blind period and 
2 day week (2nd visit). Although the onset of signiﬁcant 
clinical effect was ﬁrst noticed in the 2-week period (55% 
in both groups), the maximum improvement in headache 
frequency was achieved in 64% of patients in CIN and 59% 
of patients in VS group at the end of 12 weeks. A similar 
observation was also noted in headache duration and 
intensity. 
For the changes in duration of migraine attacks when 
compared to run-in, no statistically signiﬁcant differences 
were noted, and no time effects was observed in any of the 
treatment groups. For changes in the intensity of attacks 
when compared with run-in, statistically signiﬁcant inter 










Cinnarizine Sodium Valproate 
frequency at baseline 
frequency during the 
doubleblind period 
frequency in 2d week 
frequency in last 4 weeks 
 
Fig. 1 Mean number of attacks in the baseline period, per visits
during the double blind period, in 2nd week, and the last 4 weeks of
treatment 
 
In the CIN group the intensity of attacks was decreased by 
3.3 at 3 day visit and 4 at fourth visit, compared to a 
reduction of 2.1 at 3 day visit and 2.6 at fourth visit in SV 
group. 
The mean days free of headache ranged from 22 days at 
run-in to 27 days at endpoint. Inter group comparison of 
changes at all time points again showed no statistically 
signiﬁcant differences between the treatments. No signiﬁ­
cant intergroup differences in the mean time between two 
consecutive migraine attacks were observed, nor did 
analysis of differences with run-in demonstrated statisti­
cally signiﬁcant intergroup differences. 
Over all 26 subjects reported one or more adverse events 
during the study period: 13 subjects in each group. The 
most frequent adverse events were weight gain, somno­
lence, hair loss, vertigo, nausea, vomiting, tremor, 
abdominal pain. Five subjects discontinued prematurely 
due to adverse events; two in the CIN group with signiﬁ­
cant weight gain, and three in SV with signiﬁcant weight 
gain and sever tremor. No signiﬁcant hematological or 
hepatic side effects were seen in the subjects of both groups 
at the end of the trial. 
Discussion 
This was a double-blind trial designed to assess the efﬁcacy 
and tolerability of CIN in the prophylaxis of refractory 
migraine in comparison with the frequently used drug SV. 
We used no placebo arm in this study because it was 
immoral to use no drug in the subjects with intractable 
headache. 
A total of 125 subjects were treated (treatment period 
was 12 weeks) and 46 subjects discontinued the trial pre­
maturely but after visit 1, so all subjects were included in 
the ITT analysis. However, it could be considerable as a 
defect that 46 subjects discontinued, it maybe because of 
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severe headache in our subjects who had less compliance to 
continue their treatment. 
For two efﬁcacy parameters, mean attack frequency per 
4 weeks in the entire double-blind period and the number 
of responders, CIN was as effective as SV. No statistically 
signiﬁcant differences between the two treatment groups 
were found for any of secondary parameters (p [ 0.05): 
mean duration of migraine attacks, mean intensity of 
attacks, mean number of days without migraine, and mean 
time between two consecutive migraine attacks. The mean 
reduction of 3 day and fourth visit intensity from baseline 
were signiﬁcantly different in two groups (p \ 0.05), with 
CIN group more reduction, which may be related to more 
effectiveness of CIN than VS after 12 weeks of treatment. 
To the best of our knowledge, no other studies are 
available comparing CIN with SV, and this is the ﬁrst 
randomized double-blind clinical trial to compare the effect 
of CIN and SV on migraine headache prevention. Also as 
mentioned before, there are a few local reports of evaluating 
CIN in migraine prophylaxis; Rossi et al. [17] in an open-
label trial of 80 patients treated with CIN in which they 
reported a mean reduction of 58% in migraine monthly 
frequency and at least 66% improvement in 71% patients. 
Amelin et al. [19] in their series of 28 vertigo patients with 
migraine, also reported 65% reduction in migraine monthly 
frequency. A recently published open-label trial of ours 
showed a reduction of 75% in migraine monthly frequency 
and by 50% improvement in 86% patients [18]. 
The present results of 63.5% reduction in monthly fre­
quency and 61.2% responders are consistent with previous 
studies, which demonstrate the efﬁcacy of CIN in the 
prophylaxis of refractory migraine headache. 
In the other hand, in recent years, SV has been shown to 
have encouraging results in the prophylactic treatment of 
different headache types [22, 24, 25–28]. Erdemoglu et al. 
[22] in a study on 127 patients with refractory migraine 
headache showed 50% improvement in 67% patients. The 
beneﬁcial effect of 60% reduction in intensity of attacks 
was also observed in their study without any changes in the 
duration of attacks. Some of other studies demonstrated 
improvement in headache frequency, intensity, and dura­
tion of headache [22, 26, 28]. The results of current study 
with a mean reduction of 53.6% in monthly frequency and 
63.8% improvement in patients, in consistence with pre­
vious studies, support the efﬁcacy of SV in the prophylaxis 
of migraine. 
With respect to these results and no statistically signif­
icant differences between the two treatment groups in 
efﬁcacy parameters, CIN is as effective as SV in prophy­
laxis of refractory migraine attack. 
In both groups, also the onset of clinical effect was 
evident in the 2 day week (55% in both groups), the 
maximum effect was observed in the 12th week (64% in 
CIN group and 59% in VS group). Although these ﬁndings 
were also noted in other studies [18, 22, 29], the onset of 
effect was reported in the 4-week period which was not 
signiﬁcant. The reason for the early onset of effect and the 
delayed of onset of maximum effect could not be explained 
with the prophylactic properties of these drugs. Therefore, 
CIN and SV should be used for more than 8 weeks to 
notice the maximum effect. It may be assumed there is an 
additional effect over 12 weeks and future controlled 
studies should be extended to 16 weeks or longer. 
No statistically signiﬁcant effect of predictive factors 
included type migraine (with or without urea), sex, age, 
family history (maternal or paternal), frequency, duration, 
and intensity of migraine attacks, age of migraine onset, 
duration of migraine history, presence of concomitant 
symptoms (nausea vomiting, photophobia and phonopho­
bia), and resistance to prophylactic treatment, was observed. 
Over all 20% of subjects reported adverse events in both 
group with no signiﬁcant differences (p [ 0.05). All events 
were mild and moderate except for ﬁve patients (two in CIN 
and three in SV group), which lead to discontinued the 
study. In a previous study, in elderly people, cases of 
aggravation or an appearance of exterapyramidal symptoms 
have been described during prolonged therapy with CIN 
[30], but as migraine prevalence decline after 40 years, this 
complication usually is not the case. Although it was 
reported that monitoring of drug levels and liver function 
tests is not needed, it may be essential to prevent serious 
liver damage. Clinical examination or liver function tests 
detected no cases of hepatic injury. The most valuable test 
for adverse events is clinical observation of the patient. 
The results of this double-blind clinical trial on refrac­
tory migraine headache to propranolol and tricyclic 
antidepressants showed that CIN is an effective and safe 
prophylactic agent even in severe migraine headache after 
12 weeks of treatment. Also the onset of signiﬁcant effect 
in 2 day week of treatment is notable, and more reduction 
of headache intensity in CIN than SV. Future controlled 
trials expended longer would also support the effectiveness 
and safety of CIN in patients with refractory headache. 
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